Research advance on vasculogenic mimicry in glioma

doi:10.3760/cma.j.issn.1673-422X.2014.12.008

Abstract

Abstract: Vasculogenic mimicry (VM) is a pattern of neoplasm cells, which achieve their blood supplements through deformation and simulating capillary channels. Cumulative studies show that the formation of VM in glioma have a close relation with the glioma stem cells. In addition, some molecules such as microRNA, epithelial cell kinaseA2, vascular endothelial cadherin, transforming growth factorβ, vascular endothelial growth factor receptor2 and galectin1 play important roles in the forming process of vasculogenic mimicry. Recently, it is found that VM is associated with the poor prognosis of patients with glioma and anti angiogenesis drug efficacy. So the research on VM about the discovery, formation mechanism, prognostic impact and the clinical significance will provide an opportunity for diagnosis and therapy of glioma in early stage.

Key words: Glioma, Vasculogenic mimicry

DENG Jun, GUO Yu-Hong, GUO Geng. Research advance on vasculogenic mimicry in glioma[J]. Journal of International Oncology, 2014, 41(12): 902-905.

References

［1］ Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system［J］. Acta Neuropathol, 2007, 114(2): 97109. ［2］ Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma［J］. Clin Cancer Res, 2007, 13(4): 12531259. ［3］ Kreisl TN, Kim L, Moore K, et al. Phase Ⅱ trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma［J］. J Clin Oncol, 2009, 27(5): 740745. ［4］ Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry［J］. Am J Pathol, 1999, 155(3): 739752. ［5］ Fan YZ, Sun W. Molecular regulation of vasculogenic mimicry in tumors and potential tumortarget therapy［J］. World J Gastrointest Surg, 2010, 2(4): 117127. ［6］ Paulis YW, Soetekouw PM, Verheul HM, et al. Signalling pathways in vasculogenic mimicry［J］. Biochim Biophys Acta, 2010, 1806(1): 1828. ［7］ Zhang Y, Sun B, Zhao X, et al. Clinical significances and prognostic value of cancer stemlike cells markers and vasculogenic mimicry in renal cell carcinoma［J］. J Surg Oncol, 2013, 108(6): 414419. ［8］ Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? ［J］. J Histochem Cytochem, 2005, 53(8): 9971002. ［9］ El Hallani S, Boisselier B, Peglion F, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry［J］. Brain, 2010, 133(Pt 4): 973982. ［10］ Chen Y, Jing Z, Luo C, et al. Vasculogenic mimicrypotential target for glioblastoma therapy: an in vitro and in vivo study［J］. Med Oncol, 2012, 29(1): 324331. ［11］ Liu Z, Li Y, Zhao W, et al. Demonstration of vasculogenic mimicry in astrocytomas and effects of Endostar on U251 cells［J］. Pathol Res Pract, 2011, 207(10): 645651. ［12］ Dong J, Zhao Y, Huang Q, et al. Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation［J］. Stem Cell Rev, 2011, 7(1): 141152. ［13］ Scully S, Francescone R, Faibish M, et al. Transdifferentiation of glioblastoma stemlike cells into mural cells drives vasculogenic mimicry in glioblastomas［J］. J Neurosci, 2012, 32(37): 1295012960. ［14］ Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact［J］. J Clin Oncol, 2009, 27(34): 58485856. ［15］ Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2)［J］. Cancer Res, 2001, 61(8): 32503255. ［16］ Wu N, Zhao X, Liu M, et al. Role of microRNA26b in glioma development and its mediated regulation on EphA2［J］. PLoS One, 2011, 6(1): e16264. ［17］ Krichevsky AM, Sonntag KC, Isacson O, et al. Specific microRNAs modulate embryonic stem cellderived neurogenesis［J］. Stem Cells, 2006, 24(4): 857864. ［18］ Dong B, Mu L, Qin X, et al. Stathmin expression in gliomaderived microvascular endothelial cells: a novel therapeutic target［J］. Oncol Rep, 2012, 27(3): 714718. ［19］ Song Y, Mu L, Han X, et al. MicroRNA9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression［J］. J Neurooncol, 2013, 115(3): 381390. ［20］ Hendrix MJ, Seftor EA, Meltzer PS, et al. Expression and functional significance of VEcadherin in aggressive human melanoma cells: role in vasculogenic mimicry［J］. Proc Natl Acad Sci U S A, 2001, 98(14): 80188023. ［21］ Hess AR, Margaryan NV, Seftor EA, et al. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors［J］. Dev Dyn, 2007, 236(12): 32833296. ［22］ Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase2, and membrane type1matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma［J］. Cancer Res, 2001, 61(17): 63226327. ［23］ Mao XG, Xue XY, Wang L, et al. CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia［J］. Neuro Oncol, 2013, 15(7): 865879. ［24］ Ling G, Wang S, Song Z, et al. Transforming growth factorbeta is required for vasculogenic mimicry formation in glioma cell line U251MG［J］. Cancer Biol Ther, 2011, 12(11): 978988. ［25］ Serwe A, Rudolph K, Anke T, et al. Inhibition of TGFbeta signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol［J］. Invest New Drugs, 2012, 30(3): 898915. ［26］ Francescone R, Scully S, Bentley B, et al. Glioblastomaderived tumor cells induce vasculogenic mimicry through VEGFR2 protein activation［J］. J Biol Chem, 2012, 287(29): 2482124831. ［27］ Yao X, Ping Y, Liu Y, et al. Vascular endothelial growth factor receptor 2 (VEGFR2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stemlike cells［J］. PLoS One, 2013, 8(3): e57188. ［28］ Foltz G, Ryu GY, Yoon JG, et al. Genomewide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma［J］. Cancer Res, 2006, 66(13): 66656674. ［29］ Le Mercier M, Fortin S, Mathieu V, et al. Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression［J］. Neoplasia, 2009, 11(5): 485496. ［30］ Liu XM, Zhang QP, Mu YG, et al. Clinical significance of vasculogenic mimicry in human gliomas［J］. J Neurooncol, 2011, 105(2): 173179. ［31］ Wang SY, Ke YQ, Lu GH, et al. Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma［J］. J Neurooncol, 2013, 112(3): 339345. ［32］ Qu B, Guo L, Ma J, et al. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system［J］. Med Hypotheses, 2010, 74(2): 360361. ［33］ Xu Y, Li Q, Li XY, et al. Shortterm antivascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis［J］. J Exp Clin Cancer Res, 2012, 31: 16. ［34］郭世文, 张熙, 尉春艳. Alphastatin多肽对胶质瘤血管生成拟态的抑制作用及其相关机制［J］. 重庆医学, 2011, 40(21): 20842086.

[1]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[2]	Xiao Nan, Sun Pengfei. Research progress of oxidative stress in the sensitivity of chemoradiotherapy for gliomas [J]. Journal of International Oncology, 2022, 49(6): 357-361.
[3]	Zhu Yishuo, Cui Yujie, Liu Qi, Li Jun, Fan Yuechao. Analysis of risk factors and prediction model establishment for early postoperative recurrence in glioma patients [J]. Journal of International Oncology, 2022, 49(2): 79-83.
[4]	Kong Chunyu, Sun Pengfei. SLC7A11 and glioma [J]. Journal of International Oncology, 2022, 49(10): 604-607.
[5]	Guo Shihao, Ren Yeqing, Guo Geng. Molecular mechanism of vasculogenic mimicry in brain glioma [J]. Journal of International Oncology, 2021, 48(6): 362-365.
[6]	Wang Xianwei, Shi Meiyan, Wang Fengqin, Qi Fu, Wang Chaozhe, Zhou Fei. Roles of TSA upregulation miR-4298 targeting inhibition of PADI4 expression in inducing U251 cells apoptosis [J]. Journal of International Oncology, 2021, 48(4): 193-199.
[7]	Sun Yanqi, Ren Yeqing, Guo Geng. Mechanism of inhibitory effect of interferon and its related signal pathway on the invasion of glioma [J]. Journal of International Oncology, 2021, 48(3): 172-175.
[8]	Zhao Congxuan, Yu Tao. Mining and prediction of glioma-related genes [J]. Journal of International Oncology, 2020, 47(5): 293-296.
[9]	Nan Yang, Zhong Yue. New research advances of long non-coding RNA in glioma [J]. Journal of International Oncology, 2020, 47(2): 98-102.
[10]	Zhang Wen, Song Qibin, Hu Weiguo. Clinical application of multimodal magnetic resonance imaging in glioma [J]. Journal of International Oncology, 2020, 47(11): 686-690.
[11]	Chen Liang, Qin Jun, Lei Junrong, Liu Jun, Wang Lu. miR-1254 inhibits the proliferation and invasion of glioma cells by targeting CSF-1 [J]. Journal of International Oncology, 2020, 47(10): 577-584.
[12]	Zhang Qianhui, Zhang Yang, Su Weipeng, Zhang Song′an, Liu Pan, Zhao Huarong. Expressions of LSD1, MGMT and Ki-67 in high-grade glioma and their influences on prognosis [J]. Journal of International Oncology, 2019, 46(9): 519-525.
[13]	Yi Lin, Qiu Shi. Anti-tumor effect and mechanisms of shikonin on gliomas [J]. Journal of International Oncology, 2019, 46(8): 489-491.
[14]	Yu Xuejuan, An Hongwei, Sun Yamei, Jiang Zheng, Zhang Xuehai, Yang Wenjing, Zhang Wei. Expressions of MMP2, TIMP2, Ki-67 and P53 in glioma tissues and their significance [J]. Journal of International Oncology, 2019, 46(12): 718-722.
[15]	Lu Di, Zhang Jundong, Guo Geng, Wang Xiaogang. Research progress of interferon induced glioma cell apoptosis [J]. Journal of International Oncology, 2018, 45(7): 432-435.